Rise Therapeutics Begins Rheumatoid Arthritis Trial with First Patient

Rise Therapeutics, a Maryland-based clinical-stage biotech firm, has made a significant step forward by enrolling the first participant in its Phase 1 clinical trial for R-2487, a new oral immunotherapy for rheumatoid arthritis (RA). Gary Fanger, the company's CEO, highlighted the importance of this development for both the company and individuals living with RA, emphasizing their dedication to providing groundbreaking treatments.
RA is a prevalent chronic inflammatory condition, impacting approximately 0.24% of individuals globally and up to 1% in the United States. The condition is more common in women and can lead to severe disability in about 50% of those affected. The clinical trial, registered as NCT05961592, aims to assess the safety, pharmacodynamics, and efficacy of R-2487 in treating RA. It is set to include up to 36 participants across various locations in the U.S. and will use a range of biomarkers and pharmacodynamic assessments to measure the drug's impact.
R-2487 represents a novel approach to autoimmune disease treatment, utilizing synthetic biology to induce immune tolerance by enhancing T regulatory cells. This innovative therapy is designed to correct deficiencies in Treg cells, thereby reducing the inflammatory cytokines associated with autoimmune diseases. The drug is part of Rise Therapeutics' broader strategy to develop targeted biological medicines through their proprietary oral delivery system, which is tailored to enhance the efficiency and speed of clinical trials.
Rise Therapeutics is a private company specializing in the development of cellular-based immune therapies. The firm is committed to product innovation and maintains an in-house clinical GMP manufacturing facility, focusing on creating biological medicines with an oral biologics delivery platform.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!